Yu Qian-Sheng, Luo Weiming, Deschamps Jeffery, Holloway Harold W, Kopajtic Theresa, Katz Jonathan L, Brossi Arnold, Greig Nigel H
Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, 251 Bayview Boulevard, Baltimore, Maryland 21224, USA.
ACS Med Chem Lett. 2010 Mar 31;1(3):105-109. doi: 10.1021/ml1000189.
As a clinical medication for the treatment of hyperkinetic movement disorders, in conditions such as Huntington's disease, tetrabenazine (TBZ) has been always used in its racemic form. To establish whether or not its beneficial therapeutic actions are enantiospecific, a practical total synthetic route was developed to yield each enantiomeric form to allow their chemical and pharmacological characterization. We briefly summarize the total synthesis of TBZ and report a detailed procedure for resolution of TBZ into its enantiomers, (+)-TBZ and (-)-TBZ. This allowed determination of the optical rotation and absolute configurations of each TBZ enantiomer, based on X-ray crystallographic analysis, together with characterization of their inhibitory action at the vesicular monoamine transporter 2, where (+)-TBZ proved three-fold more active than (-)-TBZ.
作为治疗运动亢进性运动障碍的临床药物,在诸如亨廷顿舞蹈症等病症中,丁苯那嗪(TBZ)一直以来都以消旋体形式使用。为确定其有益的治疗作用是否具有对映体特异性,开发了一种实用的全合成路线来制备每种对映体形式,以便对其进行化学和药理学表征。我们简要总结了TBZ的全合成,并报告了将TBZ拆分为其对映体(+)-TBZ和(-)-TBZ的详细步骤。这使得基于X射线晶体学分析确定了每种TBZ对映体的旋光性和绝对构型,同时还对它们在囊泡单胺转运体2上的抑制作用进行了表征,结果表明(+)-TBZ的活性比(-)-TBZ高三倍。